WHO Declares Mpox a Global Health Emergency Amid Rising Cases and New Deadlier Strain

The World Health Organization (WHO) has declared mpox a global public health emergency for the second time in two years due to an outbreak that originated in the Democratic Republic of Congo (DRC) and has since spread to neighboring countries and beyond.

New cases of the virus have now been identified outside of Africa, in countries such as Thailand, the Philippines, Sweden, and Pakistan. Health authorities are raising alarms as many new cases in Africa involve a recently discovered, more lethal strain of the virus, known as clade 1b, which has also been confirmed in Thailand.

Mpox is a viral infection that spreads through close contact, including sexual contact. It presents with flu-like symptoms such as fever, chills, and muscle aches, along with pus-filled lesions. While the disease is generally mild, it can be fatal in some cases.

Two main types of mpox are identified by clades, with the current outbreak being attributed to clade 1. This strain seems to spread more easily and has a higher fatality rate compared to the clade 2 strain, which was prevalent in 2022. Clade 1 appears to disproportionately affect young people, with most fatalities occurring among children.

The rise in cases is primarily attributed to a new variant of clade 1, known as clade 1b, which is believed to be the main cause of the recent increase in cases, according to WHO. The organization noted that clade 1b is primarily transmitted from person to person, often through sexual contact. Although first identified in 2024, it likely emerged in the DRC around 2023.

“The outbreak associated with clade Ib in the DRC primarily affects adults and is spreading rapidly, sustained largely, but not exclusively, through transmission linked to sexual contact and amplified in networks associated with commercial sex and sex workers,” the WHO stated on August 19.

Aside from the DRC, clade 1b cases have been reported in Burundi, Kenya, Rwanda, Uganda, and Thailand. Clade 1 cases have also been found in the Central African Republic, the Republic of Congo, and Sweden. Meanwhile, the milder clade 2 has been identified in countries such as Cameroon, Côte d’Ivoire, Liberia, Nigeria, South Africa, the Philippines, and Pakistan.

The WHO’s declaration of a “public health emergency of international concern” is its highest level of alert and is aimed at speeding up international cooperation and public health measures to contain the disease.

“It’s clear that a coordinated international response is essential to stop these outbreaks and save lives,” said WHO Director-General Tedros Adhanom Ghebreyesus when the declaration was made on August 14. He further expressed concern over “the detection and rapid spread of a new clade of mpox in eastern DRC, its detection in neighboring countries that had not previously reported mpox, and the potential for further spread within Africa and beyond.”

Despite these concerns, Dr. Hans Kluge, the WHO’s regional director for Europe, emphasized last week that mpox should not be compared to Covid-19. In a statement released on Tuesday, Kluge dismissed parallels with the coronavirus pandemic and reassured that the risk to the general population remains low. “We can, and must, tackle mpox together — across regions and continents,” he stated.

In response to the outbreak, authorities are focusing on increasing vaccine availability, although access remains a significant challenge. The WHO is collaborating with countries and vaccine manufacturers to improve access for the nations most affected.

To date, the U.N. health agency has released $1.45 million in emergency funds and may release more in the near future. It has outlined an immediate funding requirement of $15 million for its response plan.

The Africa Centres for Disease Control and Prevention (Africa CDC) has partnered with the vaccine maker Bavarian Nordic to deliver vaccines. This partnership aims to provide 2 million doses this year and an additional 10 million doses by the end of 2025. Bavarian Nordic is also supplying vaccines to countries outside Africa and is seeking approval from the European Union’s drug regulator to extend the use of its mpox vaccine to teenagers.

The WHO’s efforts to contain the spread of mpox are focused on surveillance, public awareness, and enhancing the capacity of healthcare systems in affected regions. The agency urges countries to remain vigilant, ensure proper surveillance, and maintain strong collaboration with international health bodies to curb the further spread of the disease.